Nestle ventures into Chinese medicine with pharma deal

The world's biggest food group Nestle is moving into traditional Chinese medicine by joining forces with Chinese pharma group Chi-Med, the Swiss group said on Wednesday.

The new entity, called Partners (NSP), is to be owned equally by the two parties, Nestle said in a statement, without revealing any of the financials behind the deal.

NSP will research, develop, make and sell nutritional and medicinal products derived from botanical plants, it said.

The joint venture will also hand Nestle's Health Science division, which is handling the deal, access to Chi-Med's library, which with more than 50,000 extracts from more than 1,200 different is one of the world's largest, the statement said.

Initially, the product focus will be on gastro-intestinal health—a market worth up to $6 billion (4.6 billion euros) according to Chi-Med—but could in future expand into metabolic diseases and , Nestle said.

For Chi-Med, the deal, which is still subject to regulatory approvals, will bring "a stream of novel botanical medicines and nutritional products to market and in so doing build significant value for patients and for our shareholders," company chief executive Christian Hogg said on a conference call.

"Botanical are in the forefront in our view in the search for ," the Chi-Med chief said.

Traditional Chinese plant-based medicines represented between 30 percent and 40 percent of all pharma sales in China, he added.

This joint venture provides Nestlé Health Science with an opportunity to develop and commercialise truly innovative and scientifically validated botanical-based nutrition for personalised healthcare in gastro-intestinal health, Nestle Health Science head Luis Cantarell said.

add to favorites email to friend print save as pdf

Related Stories

Traditional folk medicine being studied

Jul 07, 2006

Researchers from both the National Institutes of Health and the cosmetics industry are studying folk medicine to come up with new products and treatments.

New drink draws criticism

Feb 12, 2007

Connecticut's attorney general has opened an investigation into the calorie-burning claims of a caffeinated drink from the Coca-Cola and Nestle companies.

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments